Evidence map›Paper›PMID 38380225›Full record

ArticleClinical Medicine Insights. Oncology2024

Breast Cancer in Young Women: Is It Different? A Single-Center Retrospective Cohort Study.

Omalkhair Abulkhair, Ahmad Omair, Dorothy Makanjuola, Manal Al Zaid, Lolwah Al Riyees, Nafisa Abdelhafiez, Emad Masuadi, Ghaida Alamri, Fatinah Althan, Abdulmohsen Alkushi and 1 more

Open access · goldAbstract read
In one paragraph

Article in Clinical Medicine Insights. Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Omalkhair AbulkhairOncology Department, Suliman Alhabib Hospital, Riyadh, Saudi Arabia.
Ahmad OmairDepartment of Basic Science, College of Science and Health Professions, King Saud bin Abdulaziz University for Health Sciences & King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.ORCID https://orcid.org/0000-0002-4246-6680
Dorothy MakanjuolaMedical Imaging Department, King Abdulaziz Medical City of National Guard & King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.ORCID https://orcid.org/0000-0003-2387-0132
Manal Al ZaidSurgery Department, King Abdulaziz Medical City of National Guard & King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
Lolwah Al RiyeesSurgery Department, King Abdulaziz Medical City of National Guard & King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
Nafisa AbdelhafiezOncology Department, King Abdulaziz Medical City of National Guard & King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
Emad MasuadiInstitute of Public Health, United Arab Emirates University, Al Ain, UAE.
Ghaida AlamriCollege of Medicine, King Saud bin Abdulaziz University for Health Sciences & King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
Fatinah AlthanWomen Imaging Department, Suliman Alhabib Hospital, Riyadh, Saudi Arabia.
Abdulmohsen AlkushiDepartment of Pathology & Laboratory Medicine, King Abdulaziz Medical City of National Guard & King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.ORCID https://orcid.org/0000-0001-9329-2097
Ann PartridgeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
King Abdulaziz Medical City · SAKing Saud bin Abdulaziz University for Health Sciences · SADana-Farber Cancer Institute · USUnited Arab Emirates University · AE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Breast cancer (BC) is one of the commonest cancers among women worldwide. Differences regarding tumor biology, presentation, genetics, and molecular subtypes may contribute to the relatively poorer prognosis among younger women. Limited information exists regarding pathologic characteristics and long-term outcomes among this group. Methods: This retrospective cohort study included 695 BC patients diagnosed over a 10-year period and investigated the clinicopathological characteristics and long-term disease outcomes among patients diagnosed at age less than or equal to 40 years compared with older ones. Cox regression analysis was performed, and Kaplan-Meier curves were generated to assess overall survival (OS). Results: Compared with the younger patients (⩽40 years) estrogen receptor (ER) and progesterone receptor (PR) expression was mainly positive in older patients (>40 years) (76.2% vs 61.3% and 64.2% vs 49.6%, respectively). The most common molecular subtype in both age groups was luminal B (44.1% in older and 40.3% in younger). A clinical complete remission after neoadjuvant therapy was observed more frequently in older patients (76.7%; N = 442) in comparison with the younger patients (66.4%; N = 79) ( Conclusion: Overall survival in women diagnosed with BC at age less than or equal to 40 years is not significantly worse than older patients. However, among patients with luminal A subtype, younger women had relatively poor survival. Further research is needed to understand this age-based disparity in outcomes.

Indexed as

Breast cancerclinicopathological characteristicslong-term outcomesoverall survival

Identifiers

PMID38380225
PMCPMC10878213
OpenAlexW4391967954

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.